Rezolute advances therapies for hypoglycemia with RZ358 and RZ402, showing efficacy in trials. Read why RZLT stock is a compelling, albeit cautious, investment.

After hours: February 21 at 4:50:40 PM EST Loading Chart for SLNO ...

This may not be the case for long. The FDA is set to decide on Soleno Therapeutics’ Prader-Willi therapy DCCR (diazoxide choline) at the end of March. This decision was delayed when the FDA ...

Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. Receive News & Ratings ...

Pre-Market: 4:56:05 a.m. EST ...